The findings stress the importance of learning how existing drugs work to repurpose them for potential use in treating other diseases.
UCLA’s Dr. Patricia Ganz is co-leading a new study to understand treatment tolerability by including the patient’s voice in cancer research.
Developed by UCLA scientists, the technique uses robots to simultaneously screen hundreds of different treatments.
“We now have a rational and logical way to develop immunotherapies going forward and a clinical development process for doing it,” said UCLA's Dr. Timothy Cloughesy.
A long-term, UCLA-led study finds that those with low- or intermediate-risk disease can safely cut treatment to four to five days.
A technique they developed coaxes pluripotent stem cells — which can can be grown indefinitely in the lab — into becoming mature T cells capable of killing tumor cells.
In this Q&A, Paul Boutros explains how scientists take cancer data, including DNA sequencing combined with clinical records, to design personal treatments.
The findings could lead to a better understanding of the metabolic needs of many different types of cancer.
Dr. David Sabatini, a Massachusetts Institute of Technology biologist and associate director of the Whitehead Institute for Biomedical Research, earned the 2018 Switzer Prize for his research into influences on cell growth.
In a lab test, half of the mice that received the treatment after having a tumor removed survived for at least 60 days without the tumor regrowing.
If future research identifies changes in how lipid behavior influences certain conditions, scientists might be able to stimulate or inhibit phospholipid-reactive T cells to treat them.
The six-year-long study about endocrine treatment is contrary to expectations.
Researchers found that lower activity of an enzyme that helps maintain cells’ health along with DNA damage were associated with worse cognitive performance, such as attention and motor skills.
The study suggests that lung cancer can be detected earlier, when it is much easier to treat.
Research led by UCLA scientists shows that dietary changes could potentially help kill cancer cells in children with leukemia.
Denise Delatorre was the first person to receive CAR T cell therapy at UCLA and the then-experimental cancer treatment eliminated all traces of non-Hodgkin’s lymphoma in her body.
When injected into mice that had acute myeloid leukemia, the combination therapy halted the disease from developing any further.
Childhood trauma, depression linked to higher risk of longer-term fatigue in breast cancer survivors
The findings may help to offer better solutions for preventing and managing fatigue.
A pioneer in her field, Dr. Linda Liau is only the second woman in the nation — and the first Asian-American woman — to chair an academic department of neurosurgery.
Researchers from the School of Dentistry and the David Geffen School of Medicine will use a technology created in the lab of Dr. David Wong from the dental school.
Previous research hinted that small cell cancers from different organs may be driven by common mechanisms, but the new study is the first to so clearly describe the steps in their evolution.
The study could lead to new treatments for a range of advanced epithelial cancers such as lung, prostate and bladder cancers.
“With this type of measurement tool, you could potentially figure out which drugs would work best for each person before even starting treatment,” said UCLA professor Dino Di Carlo.
UCLA researchers have found that an often overlooked component of a cell, the extracellular matrix, can influence how much sugar the cell consumes and its migratory behavior.
The study suggests that using pembrolizumab and SD-101 together could be effective for people whose tumors have not responded to other therapies.